Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643081 | 1.00 | CTSL (0.46) | CTSLCTSKMGLLELANEATM | |
| SCHEMBL1644722 | 0.85 | ELANE (0.47) | CTSLCTSKELANEATMCTSS | |
| SCHEMBL1644727 | 0.85 | ELANE (0.47) | CTSLCTSKELANEATMCTSS | |
| SCHEMBL1644725 | 0.85 | ELANE (0.47) | CTSLCTSKELANEATMCTSS | |
| SCHEMBL1053887 | 0.84 | CTSL (0.47) | CTSLCTSKMGLLELANEATM | |
| SCHEMBL13394496 | 0.84 | CTSL (0.47) | CTSLCTSKMGLLELANEATM | |
| SCHEMBL3483665 | 0.84 | CTSL (0.47) | CTSLCTSKMGLLELANEATM | |
| SCHEMBL1053889 | 0.84 | CTSL (0.47) | CTSLCTSKMGLLELANEATM | |
| SCHEMBL11982545 | 0.84 | CTSL (0.47) | CTSLCTSKMGLLELANEATM | |
| SCHEMBL1643061 | 0.82 | CTSK (0.47) | CTSLCTSKMGLLELANEATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER1 | CTSL 1823/4885CTSK 3326/4885MGLL 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.